A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients

C. Rodríguez, Pedro; Popa, Xitllaly; Martínez, Odeth; Mendoza, Silvia; Santiesteban, Eduardo; Crespo, Tatiana; M. Amador, Rosa; Fleytas, Ricardo; C. Acosta, Soraida; Otero, Yanine; N. Romero, Gala; de la Torre, Ana; Cala, Mireysi; Arzuaga, Lina; Vello, Loisel; Reyes, Delmairis; Futiel, Niurka; Sabates, Teresa; Catalá, Mauricio; I. Flores, Yoanna; García Verdecia, Beatriz; Viada, Carmen; Lorenzo-Luaces, Patricia; A. Marrero, Maria; Alonso, Liuba; Parra, Jenelin; Aguilera, Nadia; Pomares, Yaisel; Sierra, Patricia; Rodríguez, Gryssell; Mazorra, Zaima; Lage, Agustín; Crombet, Tania; Neninger, Elia

doi:10.1158/1078-0432.ccr-15-0855

Public

A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients

Published in Clinical Cancer Research • Feb 29, 2016

Authors:

Pedro C. Rodríguez

Xitllaly Popa

Odeth Martínez

Abstract

PURPOSE: EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAvax-EGF is a therapeutic cancer vaccine composed of human recombinant EGF conjugated to a carrier protein and Montanide ISA51 as adjuvant. The vaccine is intended to induce antibodies against self EGFs...

Subject

Medicine

Epidermal growth factor

Adverse effect

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!